Roadmap to a Global Template for Implementation of Ototoxicity Management for Cancer Treatment-Reference-Cited by-同舟云学术

Roadmap to a Global Template for Implementation of Ototoxicity Management for Cancer Treatment

Published:2024-09-12 Issue: Volume: Page:
ISSN:1538-4667
Container-title:Ear & Hearing
language:en
Short-container-title:

Author:

Fernandez Katharine¹,Hoetink Alex²³⁴⁵,Konrad-Martin Dawn⁶⁷,Berndtson Deborah⁸,Clark Khaya⁶⁷⁹¹⁰,Dreisbach Laura¹¹,Geller James I.¹²,Goffi-Gomez Maria Valeria¹³,Grosnik Amy¹²,Jamis Carmen¹⁴,Knight Kristin¹⁵,Lee David S.¹⁶,Lee John¹,Liberman Patricia Helena Pecora¹³,Milnes Trisha¹⁷,Meijer Annelot J. M.⁴⁵,Ortiz Candice E.¹⁸,Rooker Jennessa¹⁹,Sanchez Victoria A.²⁰,van den Heuvel-Eibrink Mary M.⁴⁵,Brewer Carmen C.¹,Poling Gayla L.²¹

Affiliation:

1. Division of Intramural Research, National Institute on Deafness and Other Communication Disorders, National Institutes of Health, Bethesda, Maryland, USA

2. Department of Otorhinolaryngology and Head & Neck Surgery, University Medical Center Utrecht, Utrecht, the Netherlands

3. Audiology, Utrecht Medical Center Utrecht Brain Center, Utrecht, the Netherlands

4. Audiology, Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands

5. Audiology, Wilhelmina Children’s Hospital, Utrecht, the Netherlands

6. National Center for Rehabilitative Auditory Research, Veterans Affairs Rehabilitation Research and Development, Veterans Affairs Portland Health Care System, Portland, Oregon, USA

7. Department of Otolaryngology/Head & Neck Surgery, Oregon Health & Science University, Portland, Oregon, USA

8. International Ototoxicity Management Group, Cancer Survivor and Advocate, Vienna, Virginia, USA

9. Veterans Affairs Health Services Research & Development Center of Innovation, Center to Improve Veteran Involvement in Care, VA Portland Health Care System (R&D 66), Portland, Oregon, USA

10. Department of Medical Informatics and Clinical Epidemiology, Oregon Health & Science University, Portland, Oregon, USA

11. School of Speech, Language, and Hearing Sciences, San Diego State University, San Diego, California, USA

12. Division of Audiology, Cincinnati Children’s Hospital Medical Center, Cincinnati, Ohio, USA

13. Division of Audiology, AC Camargo Cancer Center, São Paulo, Brazil

14. Head and Neck Institute, Cleveland Clinic, Cleveland, Ohio, USA

15. Department of Audiology, Doernbecher Children’s Hospital, Oregon Health & Science University, Portland, Oregon, USA

16. Department of Otolaryngology-Head and Neck Surgery, Washington University School of Medicine, St. Louis, Missouri, USA

17. Department of Audiology, Veterans Affairs Augusta Health Care System, Augusta, Georgia, USA

18. Capital Institute of Hearing & Balance, Silver Spring, Maryland, USA

19. College of Nursing, University of South Florida, Tampa, Florida, USA

20. Department of Otolaryngology-Head & Neck Surgery, University of South Florida, Tampa, Florida, USA

21. Department of Otolaryngology-Head and Neck Surgery, Mayo Clinic, Rochester, Minnesota, USA.

Abstract

Ototoxicity is among the adverse events related to cancer treatment that can have far-reaching consequences and negative impacts on quality-of-life for cancer patients and survivors of all ages. Ototoxicity management (OtoM) comprises the prevention, diagnosis, monitoring, and treatment, including rehabilitation and therapeutic intervention, of individuals who experience hearing loss, tinnitus, or balance/vestibular difficulties following exposures to ototoxic agents, including platinum chemotherapy (cisplatin, carboplatin) and cranial radiation. Despite the well-established physical, socioeconomic, and psychological consequences of hearing and balance dysfunction, there are no widely adopted standards for clinical management of cancer treatment-related ototoxicity. Consensus recommendations and a roadmap are needed to guide development of effective and feasible OtoM programs, direct research efforts, address the needs of caregivers and patients at all stages of cancer care and survivorship. Here we review current evidence and propose near-term to longer-term goals to advance OtoM in five strategic areas: (1) beneficiary awareness, empowerment, and engagement, (2) workforce enhancement, (3) program development, (4) policy, funding, and sustainability, and (5) research and evaluation. The goal is to identify needs and establish a roadmap to guide worldwide adoption of standardized OtoM for cancer treatment and improved outcomes for patients and survivors.

Publisher

Ovid Technologies (Wolters Kluwer Health)

Reference118 articles.

1. High-frequency audiometry reveals high prevalence of aminoglycoside ototoxicity in children with cystic fibrosis.;Al-Malky;J Cyst Fibros,2015

2. Position statement and clinical practice guidelines: ototoxicity monitoring.,2009

3. Guidelines for the audiologic management of individuals receiving cochleotoxic drug therapy.;ASHA,1994

4. Ototoxicity after cisplatin-based chemotherapy: Factors associated with discrepancies between patient-reported outcomes and audiometric assessments.;Ardeshirrouhanifard;Ear Hear,2022

5. Cisplatin-based chemotherapy: Add high-frequency audiometry in the regimen.;Arora;Indian J Cancer,2009